Простадоз - возможность превентивной терапии рака простаты?


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Актуальность проблемы профилактики рака предстательной железы (РПЖ) продиктована очевидным преимуществом предупреждения перед сложностью лечения заболевания. К настоящему времени опубликовано громадное количество результатов исследований как in vitro, так и in vivo оценки профилактического эффекта употребления белка, углеводов, жира, клетчатки, растительных экстрактов и других цельных продуктов и их сочетаний в диете, витаминов, микроэлементов и биологически активных веществ, медикаментов. Оптимального профилактического средства не найдено, что побудило нас к проведению собственного исследования биологически активной добавки (БАД) ПростаДоз*. Исследование выполнено на группе из 58 пациентов с повышенным уровнем простатспецифического антигена и результатами гистологического исследования, подтвердившими отсутствие РПЖ и наличие ПИН высокой степени. Спустя 6 мес. приема ПростаДоз гистологический анализ материала, полученного при повторной биопсии, выявил значимо более низкую встречаемость РПЖ и мелкоацинарной атипичной пролиферации в группе приема ПростаДоз (10,4%) по сравнению с группой контроля (20,7%; p<0,024), а в некоторых случаях даже регресс ПИН (32%) в группе приема (p=0,5). Также отмечено достоверное снижение уровня простатспецифического антигена после приема ПростаДоз. Полученные данные указывают на потенциальную эффективность его применения как химиопревентивного средства РПЖ.

Полный текст

Доступ закрыт

Об авторах

Ю. Г Аляев

Клиника урологии ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова»; НИИ уронефрологии и репродуктивного здоровья человека

Л. М Рапопорт

Клиника урологии ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова»; НИИ уронефрологии и репродуктивного здоровья человека

Д. Г Цариченко

Клиника урологии ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова»; НИИ уронефрологии и репродуктивного здоровья человека

Т. М Ганжа

Клиника урологии ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова»; НИИ уронефрологии и репродуктивного здоровья человека

Email: timurmed@hotmail.com
врач УЗД онкологического урологического отделения УКБ №2

Г. Е Крупинов

Клиника урологии ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова»; НИИ уронефрологии и репродуктивного здоровья человека

Список литературы

  1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
  2. Chyou P.H., Nomura A.M., Stemmermann G.N. A prospective study of weight, body mass index and other anthropometric measurements in relation to site-specific cancers. Int Cancer. 1994;57:313-317.
  3. Ito K. Prostate cancer in Asian men. Nat Rev Urol. 2014;11(4):197-212.
  4. Mavropoulos J.C., Isaacs W.B., Pizzo S.V. et al. Is there a role for a low-carbohydrate ketogenic diet in the management of prostate cancer? Urology. 2006;68(1):15-18.
  5. Masko E.M., Thomas J.A., Antonelli J.A. et al. Low-carbohydrate diets and prostate cancer: how low is “low enough”? Cancer Prev Res (Phila). 2010; 3:1124-1131.
  6. Drake I., Sonestedt E., Gullberg B. et al. Dietary intakes of carbohydrates in relation to prostate cancer risk: a prospective study in the Malmo Diet and Cancer cohort. Am J Clin Nutr. 2012;96:1409-1418.
  7. Levine M.E., Suarez J.A., Brandhorst S. et al. Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality in the 65 and younger but not older population. Cell Metab. 2014; 19:407-417.
  8. Richman E.L., Stampfer M.J., Paciorek A. et al. Intakes of meat, fish, poultry, and eggs and risk of prostate cancer progression. Am J Clin Nutr. 2010; 91:712-721.
  9. Joshi A.D., John E.M., Koo J. et al. Fish intake, cooking practices, and risk of prostate cancer: results from a multi-ethnic case-control study. Cancer Causes Control. 2012; 23:405-420.
  10. Joshi A.D., Corral R., Catsburg C. et al. Red meat and poultry, cooking practices, genetic susceptibility and risk of prostate cancer: results from a multiethnic case-control study. Carcinogenesis. 2012; 33:2108-2118.
  11. Catsburg C., Joshi A.D., Corral R. et al. Polymorphisms in carcinogen metabolism enzymes, fish intake, and risk of prostate cancer. Carcinogenesis. 2012; 33:1352-1359.
  12. Pettersson A., Kasperzyk J.L., Kenfield S.A. et al. Milk and dairy consumption among men with prostate cancer and risk of metastases and prostate cancer death. Cancer Epidemiol Biomarkers Prev. 2012; 21:428-436.
  13. Deneo-Pellegrini H., Ronco A.L., De Stefani E. et al. Food groups and risk of prostate cancer: a case-control study in Uruguay. Cancer Causes Control. 2012; 23:1031-1038.
  14. Park S.Y., Murphy S.P., Wilkens L.R. et al. Calcium, vitamin D and dairy product intake and prostate cancer risk: the Multiethnic Cohort Study. Am J Epidemiol. 2007; 166:1259-1269.
  15. Song Y., Chavarro J.E., Cao Y. et al. Whole milk intake is associated with prostate cancer-specific mortality among U.S. male physicians. J Nutr. 2013;143:189-196.
  16. Young N.J., Metcalfe C., Gunnell D. et al. A cross-sectional analysis of the association between diet and insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)-2, and IGFBP-3 in men in the United Kingdom. Cancer Causes Control. 2012; 23:907-917.
  17. Chiyomaru T., Yamamura S., Fukuhara S. et al. Genistein inhibits prostate cancer cell growth by targeting miR-34a and oncogenic HOTAIR. PLoS One. 2013; 8:e70372.
  18. Zhang S., Wang Y., Chen Z. et al. Genistein enhances the efficacy of cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer cells. Prostate. 2013; 73:1681-1689.
  19. van Die M.D., Bone K.M., Williams S.G. et al. Soy and soy isoflavones in prostate cancer: a systematic review and meta-analysis of randomized controlled trials. BJU Int. 2014;113:E119-E130.
  20. Pavese J.M., Krishna S.N., Bergan R.C. Genistein inhibits human prostate cancer cell detachment, invasion, and metastasis. Am J Clin Nutr. 2014;100:431S-436S.
  21. Kobayashi N., Barnard R.J., Said J. et al. Effect of low-fat diet on development of prostate cancer and Akt phosphorylation in the Hi-Myc transgenic mouse model. Cancer Res. 2008;68:3066-3073.
  22. Huang M., Narita S., Numakura K. et al. A high-fat diet enhances proliferation of prostate cancer cells and activates MCP-1/CCR2 signaling. Prostate. 2012; 72:1779-1788.
  23. Chang S.N., Han J., Abdelkader T.S. et al. High animal fat intake enhances prostate cancer progression and reduces glutathione peroxidase 3 expression in early stages of TRAMP mice. Prostate. 2014; 74:1266-1277.
  24. Crowe F.L., Key T.J., Appleby P.N. et al. Dietary fat intake and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr. 2008;87:1405-1413.
  25. Epstein M.M., Kasperzyk J.L., Mucci L.A. et al. Dietary fatty acid intake and prostate cancer survival in Orebro County, Sweden. Am J Epidemiol. 2012;176:240-252.
  26. Ohwaki K., Endo F., Kachi Y. et al. Relationship between dietary factors and prostate-specific antigen in healthy men. Urol Int. 2012; 89:270-274.
  27. Bassett J.K., Severi G., Hodge A.M. et al. Plasma phospholipid fatty acids, dietary fatty acids and prostate cancer risk. Int J Cancer. 2013; 133:1882-1891.
  28. Richman E.L., Kenfield S.A., Chavarro J.E. et al. Fat intake after diagnosis and risk of lethal prostate cancer and all-cause mortality. JAMA Intern Med. 2013; 173:1318-1326.
  29. Murai T. Cholesterol lowering: role in cancer prevention and treatment. BiolChem 2014.
  30. Zhuang L., Kim J., Adam R.M. et al. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest. 2005;115:959-968.
  31. Mostaghel E.A., Solomon K.R., Pelton K.et al. Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PLoS One. 2012;7:e30062.
  32. Morote J., Celma A., Planas J. et al. Role of serum cholesterol and statin use in the risk of prostate cancer detection and tumor aggressiveness. Int J Mol Sci. 2014; 15:13615-13623.
  33. Allott E.H., Howard L.E., Cooperberg M.R.et al. Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2014; 114:661-666.
  34. Jespersen C.G., Norgaard M., Friis S. et al. Statin use and risk of prostate cancer: A Danish population-based case-control study, 1997-2010. Cancer Epidemiol. 2014; 38:42-47.
  35. Kotani K., Sekine Y., Ishikawa S. et al. High-density lipoprotein and prostate cancer: an overview. J Epidemiol. 2013; 23:313-319.
  36. Hercberg S., Galan P., Preziosi P. et al. The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med. 2004 Nov 22; 164(21):2335-42. Erratum in: Arch Intern Med. 2005;165(3):286.
  37. Meyer F., Galan P., Douville P. et al. Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial. Int J Cancer. 2005;116(2):182-186.
  38. Leitzmann M.F., Stampfer M.J., Wu K. et al. Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst. 2003; 95(13):1004- 1007.
  39. Ip C., Dong Y., Ganther H.E. New concepts in selenium chemoprevention. Cancer Metastasis Rev. 2002;21(3-4):281-289.
  40. Menter D.G., Sabichi A.L., Lippman S.M. Selenium effects on prostate cell growth. Cancer Epidemiol Biomark Prev. 2000;9:1171 - 1182.
  41. Мазо Е.Б., Мешков В.В. Простатическая интраэпителиальная неоплазия. М.: ГЭОТАР-МЕД, 2001. 80 с.
  42. Algotar A.M., Stratton M.S., Ahmann F.R. et al. Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer. Prostate 2013;73(3):328-335.
  43. Stratton M.S., Algotar A.M., Ranger-Moore J. et al. Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer. Cancer Prev Res (Phila) 2010;3(8):1035-43.
  44. Zhang W., Joseph E., Hitchcock C. et al. Selenium glycinate supplementation increases blood glutathione peroxidase activities and decreases prostate-specific antigen readings in middle-aged US men. Nutr Res 2001;31(2):165-168.
  45. Steinbrecher A., Méplan C., Hesketh J. et al. Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men. Cancer Epidemiol Biomarkers Prev. 2010;19(11):2958-68.
  46. Gunawardena K., Murray D.K., Meikle A.W. Vitamin E and other antioxidants inhibit human prostate cancer cells through apoptosis. Prostate. 2000;44(4):287-95.
  47. Klein E.A., Thompson I.M., Lippman S.M. et al. SELECT: the selenium and vitamin E cancer prevention trial. Urol. Oncol. 2003;21:59-65.
  48. Kristal A.R., Darke A.K., Morris J.S. et al. Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst. 2014;106(3):456.
  49. Virtamo J., Taylor P.R., Kontto J. et al. Effects ofalpha-tocopherol and beta-carotene supplementation on cancer incidence and mortality: 18-year postintervention follow-up of the Alpha-tocopherol, Beta-carotene Cancer Prevention Study. Int J Cancer. 2014;135:178-185.
  50. Wang L., Sesso H.D., Glynn R.J. et al. Vitamin E and C supplementation and risk of cancer in men: posttrial follow-up in the Physicians’ Health Study II randomized trial. Am J Clin Nutr. 2014;100:915-923.
  51. Neuhouser M.L., Barnett M.J., Kristal A.R. et al. Dietary supplement use and prostate cancer risk in the carotene and retinol efficacy trial. Cancer Epidemiol Biomarkers Prev. 2009;11:2202-2206.
  52. Samykutty A., Shetty A.V., Dakshinamoorthy G. et al. Vitamin k2, a naturally occurring menaquinone, exerts therapeutic effects on both hormone-dependent and hormone-independent prostate cancer cells. Evid Based Complement Alternat Med. 2013;2013:287-358.
  53. Jamison J.M., Gilloteaux J., Taper H.S. et al. Evaluation ofthe in vitro and in vivo antitumor activities of vitamin C and K-3 combinations against human prostate cancer. J Nutr. 2001;131:158S-160S.
  54. Singh R.P., Agarwal R. Prostate cancer chemoprevention by silibinin: bench to bedside. Mol Carcinog. 2006; 45:436-442.
  55. Ting H., Deep G., Agarwal R. Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer. AAPS J. 2013; 15:707-716.
  56. Ting H.J., Deep G., Jain A.K. et al. Silibinin prevents prostate cancer cell-mediated differentiation of naive fibroblasts into cancer-associated fibroblast phenotype by targeting TGF beta2. Mol Carcinog 2014.
  57. Goel A., Aggarwal B.B. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer. 2010;62:919-930.
  58. Khan N., Adhami V.M., Mukhtar H. Apoptosis by dietary agents for prevention and treatment of prostate cancer. Endocr Relat Cancer. 2010; 17:R39-R52.
  59. Heber D. Pomegranate ellagitannins. Herbal Medicine: Biomolecular and Clinical Aspects. 2nd ed. Benzie IF, Wachtel-Galor S, editors. CRC Press, Boca Raton, FL; 2011.
  60. Pantuck A.J., Leppert J.T., Zomorodian N. et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res. 2006; 12:4018-4026.
  61. Paller C.J., Ye X., Wozniak P.J. et al. A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer. Prostate Cancer Prostatic Dis. 2013; 16:50-55.
  62. Fraser S.P., Peters A., Fleming-Jones S. et al. Resveratrol: inhibitory effects on metastatic cell behaviors and voltage-gated Na(+) channel activity in rat prostate cancer in vitro. Nutr Cancer. 2014;66:1047- 1058.
  63. Osmond G.W., Masko E.M., Tyler D.S. et al. In vitro and in vivo evaluation of resveratrol and 3,5-dihydroxy-4'-acetoxy-trans-stilbene in the treatment of human prostate carcinoma and melanoma. J Surg Res. 2013; 179:e141-e148.
  64. Klink J.C., Tewari A.K., Masko E.M. et al. Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways. Prostate. 2013; 73:754-762.
  65. Askari F., Parizi M.K., Jessri M. et al. Fruit and vegetable intake in relation to prostate cancer in Iranian men: a case-control study. Asian Pac J Cancer Prev. 2014; 15:5223-5227.
  66. Liu B., Mao Q., Cao M. et al. Cruciferous vegetables intake and risk of prostate cancer: a meta-analysis. Int J Urol. 2012;19:134-141.
  67. Hsing A.W., Chokkalingam A.P., Gao Y.T. et al. Allium vegetables and risk of prostate cancer: a population-based study. J Natl Cancer Inst. 2002; 94:1648-1651.
  68. Chan R., Lok K., Woo J. Prostate cancer and vegetable consumption. Mol Nutr Food Res. 2009;53:201-216.
  69. Thomas R., Williams M., Sharma H. et al. A double-blind, placebocontrolled randomised trial evaluating the effect of a polyphenolrich whole food supplement on PSA progression in men with prostate cancer-the UK NCRN Pomi-T study. Prostate Cancer Prostatic Dis. 2014;17:180-186.
  70. Газиев А.И. Ликопин - потенциальное средство профилактики рака и сердечно-сосудистой патологии. Вопросы биологической, медицинской и фармацевтической химии. 2001;3:3-11.
  71. Zhang X., Wang Q., Neil B. et al. Effect of lycopene on androgen receptor and prostate-specific antigen velocity. Chin Med J (Engl). 2010;123(16):2231-2236.
  72. Mariani S., Lionetto L., Cavallari M. et al. Low prostate concentration of lycopene is associated with development of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. Int J MolSci 2014;15(1):1433-1440.
  73. Mohanty N.K., Saxena S., Singh U.P. et al. Lycopene as a chemopreventive agent in the treatment of high-grade prostate intraepithelial neoplasia. Urol Oncol. 2005;23(6):383-385.
  74. Wilson K.M., Kasperzyk J.L., Rider J.R. et al. Coffee consumption and prostate cancer risk and progression in the Health Professionals Follow-up Study. J Natl Cancer Inst. 2011;103:876-884.
  75. Bosire C., Stampfer M.J., Subar A.F. et al. Coffee consumption and the risk of overall and fatal prostate cancer in the NIH-AARP Diet and Health Study. Cancer Causes Control. 2013;24:1527-1534.
  76. Arab L., Su L.J., Steck S.E. et al. Coffee consumption and prostate cancer aggressiveness among African and Caucasian Americans in a population-based study. Nutr Cancer. 2012;64:637-642.
  77. Phillips R.L., Snowdon D.A. Association of meat and coffee use with cancers of the large bowel, breast, and prostate among Seventh-Day Adventists: preliminary results. Cancer Res. 1983;43:2403s-2408s.
  78. Hsing A.W., McLaughlin J.K., Schuman L.M. et al. Diet, tobacco use, and fatal prostate cancer: results from the Lutheran Brotherhood Cohort Study. Cancer Res. 1990;50:6836-6840.
  79. Cao S., Liu L., Yin X. et al. Coffee consumption and risk of prostate cancer: a meta-analysis of prospective cohort studies. Carcinogenesis. 2014; 35:256-261.
  80. Plosker G.L., Brogden R.N. Serenoarepens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging. 1996;9(5):379-95.
  81. Аляев Ю.Г., Винаров А.З., Демидко Ю.Л., Спивак Л.Г. Результаты 10-летнего исследования эффективности и безопасности применения экстракта Serenoarepens у пациентов с риском прогрессирования аденомы предстательной железы. Урология. 2013;4:32-36.
  82. Watson W.G., Beaver M.L., Williams E.D. et al. Phytochemicals from cruciferous vegetables, epigenetics, and prostate cancer prevention. AAPSJ. 2013;11:951-961.
  83. Nelson W.G., De-Marzo A.M., Isaacs W.B. Prostate cancer. N Engl J Med. 2003;349:366-81.
  84. Adhami V.M., Siddiqui I.A., Sarfaraz S. et al. Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease. Clin Cancer Res. 2009;15(6):1947-1953.
  85. Bettuzzi S., Brausi M. et al. Chemopreventation of human prostate cancer by oral administration of green tea catehinahius in volonteers with high-grade PIN: Apreliminary report from a one-year proof-of-principle study. Cancer Res 2006;66(2): 1234-1240.
  86. Brausi M., Rizzi F., Bettuzzi S. Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. Eur Urol 2008;54(2):472-473.
  87. Redman M.W., Tangen C.M., Goodman P.J. et al. Finasteride Does Not Increase the Risk of High-Grade ProstateCancer: A Bias- Adjusted Modeling Approach Cancer Prev Res. 2008;1:174-181.
  88. Камалов А.А., Абоян М.Э., Ситдыкова М.Э. и др. Применение ПростаДоза у больных хроническим простатитом: результаты мультицентрового клинического нерандомизированного исследования. Урология. 2013;6:67-73.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2015

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах